Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias

P. Corradini, M. Ladetto, C. Voena, A. Palumbo, G. Inghirami, D. M. Knowles, M. Boccadoro, A. Pileri

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

The frequency of N- and K-ras oncogene mutations was investigated in plasma cell dyscrasias. Genomic DNAs from 128 patients were selected for this study: 30 monoclonal gammopathies of undetermined significance, 8 solitary plasmacytomas, 77 multiple myelomas (MM), and 13 plasma cell leukemias (PCL). A two-step experimental approach was devised. All samples were screened for mutations by single-strand conformation polymorphism analysis. DNA fragments displaying an altered electrophoretic mobility were further studied by direct sequencing to confirm and characterize the nature of the mutations. Ras mutations are not randomly distributed because they are detectable only in MM (9%) and PCL (30.7%). N-ras codons 12, 13, and 61 and K-ras codon 12 were found to be mutated, but N-ras codon 61 mutation was the most frequent finding (63.6%). In conclusion, ras mutations were found in PCL, and in a subset of MM characterized by advanced-stage disease and adverse prognostic parameters. Furthermore, based on our findings, it is possible to speculate that ras mutations represent a late molecular lesion in the process of multistep carcinogenesis.

Original languageEnglish
Pages (from-to)2708-2713
Number of pages6
JournalBlood
Volume81
Issue number10
Publication statusPublished - 1993

Fingerprint

Paraproteinemias
ras Genes
Chemical activation
Plasmas
Plasma Cell Leukemia
Mutation
Multiple Myeloma
Codon
Electrophoretic mobility
DNA
Polymorphism
Conformations
Monoclonal Gammopathy of Undetermined Significance
Plasmacytoma
Carcinogenesis

ASJC Scopus subject areas

  • Hematology

Cite this

Corradini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowles, D. M., ... Pileri, A. (1993). Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 81(10), 2708-2713.

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. / Corradini, P.; Ladetto, M.; Voena, C.; Palumbo, A.; Inghirami, G.; Knowles, D. M.; Boccadoro, M.; Pileri, A.

In: Blood, Vol. 81, No. 10, 1993, p. 2708-2713.

Research output: Contribution to journalArticle

Corradini, P, Ladetto, M, Voena, C, Palumbo, A, Inghirami, G, Knowles, DM, Boccadoro, M & Pileri, A 1993, 'Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias', Blood, vol. 81, no. 10, pp. 2708-2713.
Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81(10):2708-2713.
Corradini, P. ; Ladetto, M. ; Voena, C. ; Palumbo, A. ; Inghirami, G. ; Knowles, D. M. ; Boccadoro, M. ; Pileri, A. / Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. In: Blood. 1993 ; Vol. 81, No. 10. pp. 2708-2713.
@article{8218c1054dfd4bb3882c304407a7c6c4,
title = "Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias",
abstract = "The frequency of N- and K-ras oncogene mutations was investigated in plasma cell dyscrasias. Genomic DNAs from 128 patients were selected for this study: 30 monoclonal gammopathies of undetermined significance, 8 solitary plasmacytomas, 77 multiple myelomas (MM), and 13 plasma cell leukemias (PCL). A two-step experimental approach was devised. All samples were screened for mutations by single-strand conformation polymorphism analysis. DNA fragments displaying an altered electrophoretic mobility were further studied by direct sequencing to confirm and characterize the nature of the mutations. Ras mutations are not randomly distributed because they are detectable only in MM (9{\%}) and PCL (30.7{\%}). N-ras codons 12, 13, and 61 and K-ras codon 12 were found to be mutated, but N-ras codon 61 mutation was the most frequent finding (63.6{\%}). In conclusion, ras mutations were found in PCL, and in a subset of MM characterized by advanced-stage disease and adverse prognostic parameters. Furthermore, based on our findings, it is possible to speculate that ras mutations represent a late molecular lesion in the process of multistep carcinogenesis.",
author = "P. Corradini and M. Ladetto and C. Voena and A. Palumbo and G. Inghirami and Knowles, {D. M.} and M. Boccadoro and A. Pileri",
year = "1993",
language = "English",
volume = "81",
pages = "2708--2713",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias

AU - Corradini, P.

AU - Ladetto, M.

AU - Voena, C.

AU - Palumbo, A.

AU - Inghirami, G.

AU - Knowles, D. M.

AU - Boccadoro, M.

AU - Pileri, A.

PY - 1993

Y1 - 1993

N2 - The frequency of N- and K-ras oncogene mutations was investigated in plasma cell dyscrasias. Genomic DNAs from 128 patients were selected for this study: 30 monoclonal gammopathies of undetermined significance, 8 solitary plasmacytomas, 77 multiple myelomas (MM), and 13 plasma cell leukemias (PCL). A two-step experimental approach was devised. All samples were screened for mutations by single-strand conformation polymorphism analysis. DNA fragments displaying an altered electrophoretic mobility were further studied by direct sequencing to confirm and characterize the nature of the mutations. Ras mutations are not randomly distributed because they are detectable only in MM (9%) and PCL (30.7%). N-ras codons 12, 13, and 61 and K-ras codon 12 were found to be mutated, but N-ras codon 61 mutation was the most frequent finding (63.6%). In conclusion, ras mutations were found in PCL, and in a subset of MM characterized by advanced-stage disease and adverse prognostic parameters. Furthermore, based on our findings, it is possible to speculate that ras mutations represent a late molecular lesion in the process of multistep carcinogenesis.

AB - The frequency of N- and K-ras oncogene mutations was investigated in plasma cell dyscrasias. Genomic DNAs from 128 patients were selected for this study: 30 monoclonal gammopathies of undetermined significance, 8 solitary plasmacytomas, 77 multiple myelomas (MM), and 13 plasma cell leukemias (PCL). A two-step experimental approach was devised. All samples were screened for mutations by single-strand conformation polymorphism analysis. DNA fragments displaying an altered electrophoretic mobility were further studied by direct sequencing to confirm and characterize the nature of the mutations. Ras mutations are not randomly distributed because they are detectable only in MM (9%) and PCL (30.7%). N-ras codons 12, 13, and 61 and K-ras codon 12 were found to be mutated, but N-ras codon 61 mutation was the most frequent finding (63.6%). In conclusion, ras mutations were found in PCL, and in a subset of MM characterized by advanced-stage disease and adverse prognostic parameters. Furthermore, based on our findings, it is possible to speculate that ras mutations represent a late molecular lesion in the process of multistep carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0027212420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027212420&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 2708

EP - 2713

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -